作者: Paul William Glue , Peter C. Hiestand , Carolyn Ann Foster
DOI:
关键词: Pharmacology 、 Immunology 、 Sphingosine-1-phosphate receptor 、 Demyelinating disease 、 Demyelinating Disorder 、 Agonist 、 Medicine 、 Multiple sclerosis 、 Sequence (medicine)
摘要: Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith Guillain-Barre syndrome, co-administration, concomitantly in sequence, of therapeutically effective amount a) an and b) co-agent shown to have clinical activity against symptom disease.